Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)
- PMID: 12461301
- DOI: 10.1111/j.1524-6175.2002.02045.x
Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)
Abstract
Context: Blood pressure control (<140/90 mm Hg) rates for hypertension fall far short of the US national goal of 50% or more. Achievable control rates in varied practice settings and geographic regions and factors that predict improved blood pressure control are not well identified.
Objective: To determine the success and predictors of blood pressure control in a large hypertension trial involving a multiethnic population in diverse practice settings.
Design: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial is a randomized, double-blind, active-controlled clinical trial with a mean follow-up of 4.9 years. Participant enrollment began in February 1994 and follow-up was completed in March 2002.
Setting: A total of 623 centers in the United States, Canada, and the Caribbean.
Participants: A total of 33,357 participants (aged > or =55 years) with hypertension and at least one other coronary heart disease risk factor.
Interventions: Participants were randomly assigned to receive (double-blind) chlorthalidone, 12.5-25 mg/d (n=15,255), amlodipine 2.5-10 mg/d (n=9048), or lisinopril 10-40 mg/d (n=9054) after other medication was discontinued. Doses were increased within these ranges and additional drugs from other classes were added as needed to achieve blood pressure control (<140/90 mm Hg).
Main outcome measures: The outcome measures for this report are systolic and diastolic blood pressure, the proportion of participants achieving blood pressure control (<140/90 mm Hg), and the number of drugs required to achieve control in all three groups combined.
Results: Mean age was 67 years, 47% were women, 35% black, 36% diabetic; 90% were on antihypertensive drug treatment at entry. At the first of two pre-randomization visits, blood pressure was <140/90 mm Hg in only 27.4% of participants. After 5 years of follow-up, the percent controlled improved to 66%. Systolic blood pressure was <140 mm Hg in 67% of participants, diastolic blood pressure was <90 mm Hg in 92%, the mean number of drugs prescribed was 2.0+/-1.0, and the percent on > or =2 drugs was 63%. Blood pressure control varied by geographic regions, practice settings, and demographic and clinical characteristics of participants.
Conclusions: These data demonstrate that blood pressure may be controlled in two thirds of a multiethnic hypertensive population in diverse practice settings. Systolic blood pressure is more difficult to control than diastolic blood pressure, and at least two antihypertensive medications are required for most patients to achieve blood pressure control. It is likely that the majority of people with hypertension could achieve a blood pressure <140/90 mm Hg with the antihypertensive medications available today.
Copyright 2002 Le Jacq Communications, Inc.
Comment in
-
High blood pressure control: put the champagne away.J Clin Hypertens (Greenwich). 2002 Nov-Dec;4(6):391-2. doi: 10.1111/j.1524-6175.2002.02076.x. J Clin Hypertens (Greenwich). 2002. PMID: 12461300 Free PMC article.
Similar articles
-
Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group.JAMA. 2000 Apr 19;283(15):1967-75. JAMA. 2000. PMID: 10789664 Clinical Trial.
-
Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).JAMA. 2002 Dec 18;288(23):2981-97. doi: 10.1001/jama.288.23.2981. JAMA. 2002. PMID: 12479763 Clinical Trial.
-
Relationship of antihypertensive treatment regimens and change in blood pressure to risk for heart failure in hypertensive patients randomly assigned to doxazosin or chlorthalidone: further analyses from the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial.Ann Intern Med. 2002 Sep 3;137(5 Part 1):313-20. doi: 10.7326/0003-4819-137-5_part_1-200209030-00006. Ann Intern Med. 2002. PMID: 12204014 Clinical Trial.
-
[ALLHAT trial--antithesis to the overuse of vasodilating antihypertensive drugs].Nihon Rinsho. 2004 Mar;62 Suppl 3:648-53. Nihon Rinsho. 2004. PMID: 15171450 Review. Japanese. No abstract available.
-
Recommendations for the management of special populations: racial and ethnic populations.Am J Hypertens. 2003 Nov;16(11 Pt 2):50S-54S. doi: 10.1016/j.amjhyper.2003.07.007. Am J Hypertens. 2003. PMID: 14625162 Review.
Cited by
-
Utilisation and Tolerability of Aliskiren in the Primary Care Setting in England.J Clin Hypertens (Greenwich). 2016 Dec;18(12):1237-1243. doi: 10.1111/jch.12852. Epub 2016 Jun 3. J Clin Hypertens (Greenwich). 2016. PMID: 27255757 Free PMC article.
-
Renal sympathetic denervation in resistant hypertension.World J Cardiol. 2013 Apr 26;5(4):94-101. doi: 10.4330/wjc.v5.i4.94. World J Cardiol. 2013. PMID: 23675555 Free PMC article.
-
Resistant hypertension: do all definitions describe the same patients?J Hum Hypertens. 2015 Sep;29(9):530-4. doi: 10.1038/jhh.2014.128. Epub 2015 Jan 15. J Hum Hypertens. 2015. PMID: 25589214
-
Resistant Hypertension: An Incurable Disease or Just a Challenge For Our Medical Skill?High Blood Press Cardiovasc Prev. 2016 Dec;23(4):347-353. doi: 10.1007/s40292-016-0159-y. Epub 2016 May 17. High Blood Press Cardiovasc Prev. 2016. PMID: 27188195 Review.
-
Comparison of First-Line Dual Combination Treatments in Hypertension: Real-World Evidence from Multinational Heterogeneous Cohorts.Korean Circ J. 2020 Jan;50(1):52-68. doi: 10.4070/kcj.2019.0173. Epub 2019 Aug 28. Korean Circ J. 2020. PMID: 31642211 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical